DelveInsight Blog
Related Article
BeiGene’s BRUKINSA Gets FDA Accelerated Approval; GSK’s Positive Results in DREAMM-8 Phase III; Sandoz’s Denosumab Biosimilars FDA Approved; Terns Pharma’s TERN-701 Receives Orphan Drug Designation; Wegovy® Approved in US for Overweight Cardiovascular Risk; Travere Therapeutics Submits sNDA for FILSPARI IgAN Full Approval
BeiGene Receives FDA Accelerated Approval for BRUKINSA in Relapsed/Refractory Follicular Lymphoma BeiGene, Ltd., has declared that the FDA has provided accelerated approval for BRUKINSA® (zanubrutinib) to be used in treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), when used alo...
Find MoreBiosurgery: Advancing Medicine through Biologically Derived Solutions
In recent years, the healthcare and medical devices market has undergone a remarkable transformation, largely fueled by advancements in technology and growth in innovation. One of the major standout developments in the healthcare industry is the rise of the biosurgery market and the related product demand, whic...
Find MorePacemakers: Analyzing the Market Dynamics and Major Developments
Over the past few decades, the prevalence of cardiovascular diseases has grown significantly, leading to very high mortality and morbidity worldwide. CVDs are a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other condition...
Find MoreEditor's Pick
Newsletter/Whitepaper
Recent Article
ASCO Conference 2023
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.